Core Viewpoint - Analysts project that Bausch Health (BHC) will report quarterly earnings of $1.12 per share, reflecting a year-over-year decline of 2.6%, while revenues are expected to reach $2.51 billion, an increase of 4.3% from the same quarter last year [1]. Earnings Projections - Over the last 30 days, the consensus EPS estimate for the quarter has been revised upward by 0.8%, indicating a collective reassessment by covering analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Total Bausch + Lomb revenues are estimated at $1.23 billion, representing a year-over-year increase of 4.8% [5]. - Revenues from Diversified Products are projected to be $252.98 million, indicating a decline of 2.3% year over year [5]. - Total Bausch Health revenues (excluding B+L) are expected to reach $1.26 billion, reflecting a year-over-year increase of 2.1% [5]. Segment-Specific Revenue Forecasts - Revenues from Salix are forecasted at $598.47 million, showing a year-over-year increase of 2.7% [6]. - Solta Medical revenues are expected to be $115.36 million, indicating a 12% increase from the prior year [6]. - International revenues are projected to reach $294.30 million, reflecting a year-over-year increase of 1.5% [6]. Bausch + Lomb Product Revenues - Vision Care revenues are expected to be $698.94 million, indicating a year-over-year increase of 5.6% [7]. - Surgical revenues are projected at $213.60 million, reflecting a 4.7% increase year over year [7]. - Revenues from Diversified Products in Ortho Dermatology are expected to be $59.93 million, indicating a decline of 1.8% year over year [7]. Additional Product Revenue Estimates - Revenues from Diversified Products in Dentistry are projected at $23.49 million, reflecting a significant decline of 19% from the prior year [8]. - Revenues from Diversified Products in Generics are expected to be $17.13 million, indicating a substantial decline of 38.8% year over year [8]. - Neuro-related revenues are estimated at $159.79 million, reflecting a year-over-year increase of 13.3% [9]. Stock Performance - Over the past month, Bausch shares have declined by 17.2%, contrasting with the Zacks S&P 500 composite's increase of 4.7% [9].

Core Viewpoint - Bausch Health (BHC) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2024, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for Bausch's quarterly earnings is $1.12 per share, reflecting a year-over-year decrease of 2.6%, while revenues are projected to reach $2.51 billion, representing a 4.3% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 0.75% higher, indicating a collective reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Bausch is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.74%, indicating a bearish outlook from analysts [10][11]. Historical Performance - In the last reported quarter, Bausch exceeded the expected earnings of $1.03 per share by delivering $1.12, achieving a surprise of +8.74%. Over the past four quarters, the company has beaten consensus EPS estimates twice [12][13]. Investment Considerations - Despite the potential for an earnings beat, Bausch does not appear to be a compelling candidate for such an outcome, and investors should consider other factors before making investment decisions [14][16].

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Skincare Devices - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Skincare Devices was valued at USD 14.1 Billion in 2024 and is projected to reach USD 24.5 Billion by 2030, growing at a CAGR of 9.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Report Features: Comprehensive Market D ...

Bausch Health (BHC) closed the last trading session at $7.57, gaining 3.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $9.50 indicates a 25.5% upside potential.The average comprises six short-term price targets ranging from a low of $6 to a high of $12, with a standard deviation of $2.59. While the lowest estimate indicates a decline of 20.7% from the current price level, the m ...

TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced today that it has entered into an option agreement granting leading global eye health company Bausch + Lomb the right to acquire the company. This strategic move aligns with a shared goal of advancing groundbreaking treatments addressing unmet medical needs in ophthalmology. InflammX’s pipelin ...

Bausch Health Companies (NYSE: BHC , TSX: BHC:CA ) is one of the undervalued stocks currently, trading only at trailing EV/EBITDA of 8.03x. The expected complete spin-off of its Bausch + Lomb ( BLCO ) will have more benefitHi there! I am an equity research analyst by profession but a trader by heart, with a background in accounting. I try my best to be a responsible investor, guided by my expertise in fundamental and technical analysis. I enjoy surfing and riding the trends about equity, currencies and cryp ...

A month has gone by since the last earnings report for Bausch Health (BHC) . Shares have lost about 11.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Bausch due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boo ...

Investors might want to bet on Bausch Health (BHC) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing ea ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Bausch Health (BHC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bausch Health is a member of the Medical sector. This group includes 1024 individual stocks and c ...

Shares of Bausch Health Companies Inc. (BHC) gained 12.6% after the company reported better-than-expected third-quarter results on Oct. 30. The company also raised its annual revenue guidance.Adjusted earnings per share of $1.12 beat the Zacks Consensus Estimate of $1.03. The reported figure increased from $1.03 in the year-ago quarter due to higher revenues.Total revenues of $2.5 billion were up 12% year over year. The top line also beat the Zacks Consensus Estimate of $2.4 billion.Excluding the impact of ...